Subbiah M T, Yunker R L, Rymaszewski Z, Kottke B A, Bale L K
Biochim Biophys Acta. 1987 Aug 15;920(3):251-8. doi: 10.1016/0005-2760(87)90102-0.
Effect of cholestyramine treatment in early life of Watanabe heritable hyperlipidemic rabbits (an animal model lacking low-density lipoprotein receptor activity) on subsequent (6 months recovery) occurrence of natural atherosclerotic lesion and arterial cholesterol metabolism was investigated. Initial cholestyramine treatment decreased both plasma total cholesterol and HDL-cholesterol levels which normalized within 4 weeks after treatment was discontinued. At 9 months of age (age of occurrence of spontaneous atherosclerotic lesions), the extent of aortic atherosclerosis in cholestyramine pre-treated animals was modestly lower (P less than 0.05), as compared to controls, with a significant (P less than 0.05) decrease in aortic cholesteryl ester content. Furthermore, at the end of the recovery period aortic activity of acyl-CoA: cholesterol acyltransferase and neutral cholesterol esterase activity was significantly (P less than 0.05) lower in cholestyramine-pretreated animals. These studies show that early cholestyramine pre-treatment in a low-density lipoprotein receptor-deficient animal model causes persistent changes which might influence cholesteryl ester accumulation and atherogenesis in adult life, even after cholestyramine treatment is discontinued.
研究了消胆胺治疗对渡边遗传性高脂血症兔(一种缺乏低密度脂蛋白受体活性的动物模型)早期生活中随后(6个月恢复期)自然动脉粥样硬化病变的发生及动脉胆固醇代谢的影响。最初的消胆胺治疗降低了血浆总胆固醇和高密度脂蛋白胆固醇水平,在停药后4周内恢复正常。在9个月龄(自发动脉粥样硬化病变出现的年龄)时,与对照组相比,消胆胺预处理动物的主动脉粥样硬化程度略低(P<0.05),主动脉胆固醇酯含量显著降低(P<0.05)。此外,在恢复期结束时,消胆胺预处理动物的酰基辅酶A:胆固醇酰基转移酶的主动脉活性和中性胆固醇酯酶活性显著降低(P<0.05)。这些研究表明,在低密度脂蛋白受体缺陷动物模型中早期进行消胆胺预处理会导致持续变化,这可能会影响成年期胆固醇酯的积累和动脉粥样硬化的发生,即使在停用消胆胺治疗后也是如此。